Karyopharm (KPTI) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Downgraded | Buy → Neutral | $3.00 from $13.00 | Jul 31, 2026 |
| Piper Sandler | Maintained | Overweight | $7.00 from $16.00 | Jul 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $8.00 | May 6, 2026 |
| Piper Sandler | Maintained | Overweight | $16.00 from $8.00 | Apr 27, 2026 |
| Piper Sandler | Maintained | Overweight | $8.00 from $12.00 | Mar 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 from $15.00 | Mar 25, 2026 |
| Baird | Maintained | Outperform | $15.00 from $21.00 | Mar 25, 2026 |
| Rodman & Renshaw | Initiated Coverage | Buy | $28.00 | Mar 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 | Feb 18, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Feb 5, 2026 |
| RBC Capital | Maintained | Outperform | $19.00 from $30.00 | Nov 4, 2025 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $15.00 | Oct 13, 2025 |
| Baird | Maintained | Outperform | $21.00 from $25.00 | Oct 9, 2025 |
| Piper Sandler | Maintained | Overweight | $12.00 from $15.00 | Oct 9, 2025 |
| Baird | Maintained | Outperform | $25.00 from $42.00 | Aug 12, 2025 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Jul 16, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $27.00 | Jul 11, 2025 |
| Baird | Maintained | Outperform | $42.00 from $54.00 | May 13, 2025 |
| Barclays | Maintained | Overweight | $10.00 from $5.00 | May 13, 2025 |
| RBC Capital | Maintained | Outperform | $33.00 from $34.00 | May 13, 2025 |
Frequently asked questions
Is KPTI a buy, sell, or hold?
Analysts covering Karyopharm currently average a Buy rating: 5 buy, 1 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on KPTI?
On Jul 31, 2026, HC Wainwright & Co. downgraded Karyopharm to Neutral with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.